The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study
- PMID: 12879326
- DOI: 10.1007/s00234-003-1040-y
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study
Abstract
Previous magnetic resonance spectroscopy (MRS) studies have shown increased myo-inositol (MI) and decreased N-acetyl aspartate (NAA) levels in the parieto-occipital lobes of patients with Alzheimer's disease (AD) compared to those with other dementias and normal subjects. This study aimed to establish the quantitative relationship between metabolite ratios and degree of cognitive impairment in patients with mild to moderate AD and sub-cortical ischaemic vascular dementia (SIVD). Forty-four older people with clinical dementia were recruited from a memory clinic and followed up for 2.0-3.5 years; 20 cases were finally classified as probable AD, 18 as SIVD and 6 as mixed type. Mini Mental State Examination (MMSE) and short echo time single voxel automated MRS from the mesial parieto-occipital lobes were performed at the time of initial referral. Spearman rank correlation coefficients were calculated for MMSE scores and measured metabolite ratios MI/Cr, NAA/Cr, Cho/Cr and NAA/MI. The AD group showed a significant correlation between MMSE and NAA/MI (r=0.54, P=0.014) and NAA/Cr (r=0.48, P=0.033), and a negative, non-significant association with MI/Cr (r=-0.41, P=0.072). MI/Cr was negatively correlated with NAA/Cr (r=-0.51, P=0.021). Neither Cho/Cr ratios nor age correlated with cognitive function. The SIVD group showed no correlation between any of the measured metabolite ratios and MMSE score. This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive impairment in AD. MRS may have a role in evaluating disease progression and therapeutic monitoring in AD, as new treatments become available.
Similar articles
-
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1313-22. doi: 10.1016/j.pnpbp.2004.08.013. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15588758
-
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.Dement Geriatr Cogn Disord. 2008;26(1):15-25. doi: 10.1159/000140624. Epub 2008 Jun 20. Dement Geriatr Cogn Disord. 2008. PMID: 18566544 Clinical Trial.
-
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.Neurol Res. 2004 Jul;26(5):488-95. doi: 10.1179/016164104225017640. Neurol Res. 2004. PMID: 15265265 Review.
-
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.Acta Radiol. 2009 Apr;50(3):312-9. doi: 10.1080/02841850802709219. Acta Radiol. 2009. PMID: 19235582
-
[Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus].Arq Neuropsiquiatr. 2001 Dec;59(4):865-70. doi: 10.1590/s0004-282x2001000600006. Arq Neuropsiquiatr. 2001. PMID: 11733829 Review. Portuguese.
Cited by
-
Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.Childs Nerv Syst. 2008 Jul;24(7):807-13. doi: 10.1007/s00381-007-0576-2. Epub 2008 Feb 22. Childs Nerv Syst. 2008. PMID: 18293002 Free PMC article. Clinical Trial.
-
Postoperative changes in cerebral metabolites associated with cognitive improvement and impairment after carotid endarterectomy: a 3T proton MR spectroscopy study.AJNR Am J Neuroradiol. 2013 May;34(5):976-82. doi: 10.3174/ajnr.A3344. Epub 2012 Nov 1. AJNR Am J Neuroradiol. 2013. PMID: 23124640 Free PMC article. Clinical Trial.
-
Neuroradiological findings in vascular dementia.Neuroradiology. 2007 Jan;49(1):1-22. doi: 10.1007/s00234-006-0156-2. Epub 2006 Nov 18. Neuroradiology. 2007. PMID: 17115204 Review.
-
Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.CNS Drugs. 2006;20(10):867-77. doi: 10.2165/00023210-200620100-00006. CNS Drugs. 2006. PMID: 16999455 Clinical Trial.
-
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.J Neurol. 2008 Nov;255(11):1712-20. doi: 10.1007/s00415-008-0006-8. Epub 2008 Aug 1. J Neurol. 2008. PMID: 19156487
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical